This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Raposinho, P. D. Articles by Aubert, M. L. Search for Related Content PubMed PubMed Citation Articles by Raposinho, P. D. Articles by Aubert, M. L.

Chronic Blockade of the Melanocortin 4 Receptor Subtype Leads to Obesity Independently of Neuropeptide Y Action, with No Adverse Effects on the Gonadotropic and Somatotropic Axes¹

Division of Biology of Growth and Reproduction, Department of Pediatrics, University of Geneva School of Medicine (P.D.R., V.D., P.B., M.L.A.), 1211 Geneva 14, Switzerland; and Division of Endocrinology and Metabolism, Centre Hospitalier Universidaire Vaudois, University of Lausanne School of Medicine (E.C., F.P.P.), 1011 Lausanne, Switzerland

Address all correspondence and requests for reprints to: Dr. M. L. Aubert, Hôpital des Enfants, HUGs, 6 rue Willy-Donzé, 1211 Geneva 14, Switzerland. E-mail: aubert{at}cmu.unige.ch

Neuropeptide Y (NPY) is a powerful orexigenic factor, and MSH is a melanocortin (MC) peptide that induces satiety by activating the MC4 receptor subtype. Genetic models with disruption of MC4 receptor signaling are associated with obesity. In the present study, a 7-day intracerebroventricular infusion to male rats of either the MC receptor antagonist SHU9119 or porcine NPY (10 nmol/day) was shown to strongly stimulate food and water intake and to markedly increase fat pad mass. Very high plasma leptin levels were found in NPY-treated rats (27.1 ± 1.8 ng/ml compared with 9.9 ± 0.9 ng/ml in SHU9119-treated animals and 2.1 ± 0.2 ng/ml in controls). As expected, NPY infusion induced hypogonadism, characterized by an impressive decrease in seminal vesicle and prostate weights. No such effects were seen with the SHU9119 infusion. Similarly, whereas the somatotropic axis of NPY-treated rats was fully inhibited, this axis was normally activated in the obese SHU9119-treated rats. Chronic infusion of SHU9119 strikingly reduced hypothalamic gene expression for NPY (65.2 ± 3.6% of controls), whereas gene expression for POMC was increased (170 ± 19%). NPY infusion decreased hypothalamic gene expression for both POMC and NPY (70 ± 9% and 75.4 ± 9.5%, respectively). In summary, blockade of the MC4 receptor subtype by SHU9119 was able to generate an obesity syndrome with no apparent side-effects on the reproductive and somatotropic axes. In this situation, it is unlikely that hyperphagia was driven by increased NPY release, because hypothalamic NPY gene expression was markedly reduced, suggesting that hyperphagia mainly resulted from loss of the satiety signal driven by MC peptides. NPY infusion produced hypogonadism and hyposomatotropism in the face of markedly elevated plasma leptin levels and an important reduction in hypothalamic POMC synthesis. In this situation NPY probably acted both by exacerbating food intake through Y receptors and by reducing the satiety signal driven by MC peptides.

This article has been cited by other articles:

				A. D. Strader, H. Shi, R. Ogawa, R. J. Seeley, and O. Reizes The Effects of the Melanocortin Agonist (MT-II) on Subcutaneous and Visceral Adipose Tissue in Rodents J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1153 - 1161. [Abstract] [Full Text] [PDF]

				R. M. Luque, Z. H. Huang, B. Shah, T. Mazzone, and R. D. Kineman Effects of leptin replacement on hypothalamic-pituitary growth hormone axis function and circulating ghrelin levels in ob/ob mice Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E891 - E899. [Abstract] [Full Text] [PDF]

				E Kim, S Sohn, M Lee, J Jung, R D Kineman, and S Park Differential responses of the growth hormone axis in two rat models of streptozotocin-induced insulinopenic diabetes J. Endocrinol., February 1, 2006; 188(2): 263 - 270. [Abstract] [Full Text] [PDF]

				C. Morens, M. Keijzer, K. de Vries, A. Scheurink, and G. van Dijk Effects of high-fat diets with different carbohydrate-to-protein ratios on energy homeostasis in rats with impaired brain melanocortin receptor activity Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2005; 289(1): R156 - R163. [Abstract] [Full Text] [PDF]

				N Hoggard, D V Rayner, S L Johnston, and J R Speakman Peripherally administered [Nle4,D-Phe7]-{alpha}-melanocyte stimulating hormone increases resting metabolic rate, while peripheral agouti-related protein has no effect, in wild type C57BL/6 and ob/ob mice J. Mol. Endocrinol., December 1, 2004; 33(3): 693 - 703. [Abstract] [Full Text] [PDF]

				P. D. Raposinho, T. Pedrazzini, R. B. White, R. D. Palmiter, and M. L. Aubert Chronic Neuropeptide Y Infusion into the Lateral Ventricle Induces Sustained Feeding and Obesity in Mice Lacking Either Npy1r or Npy5r Expression Endocrinology, January 1, 2004; 145(1): 304 - 310. [Abstract] [Full Text] [PDF]

				T. M. Mizuno, K. A. Kelley, G. M. Pasinetti, J. L. Roberts, and C. V. Mobbs Transgenic Neuronal Expression of Proopiomelanocortin Attenuates Hyperphagic Response to Fasting and Reverses Metabolic Impairments in Leptin-Deficient Obese Mice Diabetes, November 1, 2003; 52(11): 2675 - 2683. [Abstract] [Full Text] [PDF]

				J. R. HOLDER and C. HASKELL-LUEVANO Melanocortin Tetrapeptides Modified at the N-Terminus, His, Phe, Arg, and Trp Positions Ann. N.Y. Acad. Sci., June 1, 2003; 994(1): 36 - 48. [Abstract] [Full Text] [PDF]

				A. C. FOSTER, M. JOPPA, S. MARKISON, K. R. GOGAS, B. A. FLECK, B. J. MURPHY, M. WOLFF, M. J. CISMOWSKI, N. LING, V. S. GOODFELLOW, et al. Body Weight Regulation by Selective MC4 Receptor Agonists and Antagonists Ann. N.Y. Acad. Sci., June 1, 2003; 994(1): 103 - 110. [Abstract] [Full Text] [PDF]

				Y. Yang, M. Chen, Y. Lai, I. Gantz, K. E. Georgeson, and C. M. Harmon Molecular Determinants of Human Melanocortin-4 Receptor Responsible for Antagonist SHU9119 Selective Activity J. Biol. Chem., May 31, 2002; 277(23): 20328 - 20335. [Abstract] [Full Text] [PDF]

				D. K. Sindelar, P. Mystkowski, D. J. Marsh, R. D. Palmiter, and M. W. Schwartz Attenuation of Diabetic Hyperphagia in Neuropeptide Y-Deficient Mice Diabetes, March 1, 2002; 51(3): 778 - 783. [Abstract] [Full Text] [PDF]

				K. Baran, E. Preston, D. Wilks, G. J. Cooney, E. W. Kraegen, and A. Sainsbury Chronic Central Melanocortin-4 Receptor Antagonism and Central Neuropeptide-Y Infusion in Rats Produce Increased Adiposity by Divergent Pathways Diabetes, January 1, 2002; 51(1): 152 - 158. [Abstract] [Full Text] [PDF]

				M. W. Schwartz Brain Pathways Controlling Food Intake and Body Weight Experimental Biology and Medicine, December 1, 2001; 226(11): 978 - 981. [Abstract] [Full Text] [PDF]